BioVie Inc (BIVI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.00-1.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BIVI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development of bezisterim focusing on early-stage Parkinson's disease with proof-of-mechanism and proof-of-concept trials.
Newly stated in 2026-Q3. The Phase 2 SUNRISE-PD trial topline results showed bezisterim improved clinical motor and non-motor symptoms and biomarkers in early Parkinson's disease patients compared to placebo, with statistically significant composite endpoint improvements. This is the first quarter management publicly disclosed these results, indicating initial delivery of clinical development milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease”
Develop bezisterim to modulate neuroinflammation and insulin resistance pathways implicated in Parkinson's, Alzheimer's, and Long COVID.
Newly stated in 2026-Q3. Management described bezisterim's mechanism as reducing neuroinflammation and improving insulin sensitivity, targeting pathways relevant to multiple neurological diseases. While no financial metrics are available, this strategic product focus was clearly articulated in the recent press release.
“Bezisterim targets neuroinflammation and insulin resistance, modulating ERK, NFκB, TNFα pathways”
Develop therapies that improve both motor and non-motor symptoms to meet significant unmet needs in Parkinson’s disease patients.
Newly stated in 2026-Q3. Management emphasized bezisterim's potential to improve both motor and non-motor symptoms, addressing unmet clinical needs in Parkinson's disease. No revenue or profit data is available to measure financial impact, but the clinical trial results support this strategic priority.
“Bezisterim may address significant unmet clinical needs in Parkinson’s disease beyond motor symptoms”
Over the trailing year it converted 0.71x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.